Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses

Gerwin D Rodenburg; Elske J M van Gils; Reinier H Veenhoven; Nienke Jones; Irina Tcherniaeva; Eelko Hak; Loek van Alphen; Guy A M Berbers; Elisabeth A M Sanders

doi:10.1016/j.vaccine.2009.10.151

Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses

Gerwin D Rodenburg, Elske J M van Gils, Reinier H Veenhoven, Nienke Jones, Irina Tcherniaeva, Eelko Hak, Loek van Alphen, Guy A M Berbers, Elisabeth A M Sanders

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

271 Downloads (Pure)

Abstract

In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (C) 2009 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	1391-1396
Number of pages	6
Journal	Vaccine
Volume	28
Issue number	5
DOIs	https://doi.org/10.1016/j.vaccine.2009.10.151
Publication status	Published - 3-Feb-2010

Keywords

Pneumococcal conjugate vaccine
Immunogenicity
Reduced-dose schedules
STREPTOCOCCUS-PNEUMONIAE
NASOPHARYNGEAL CARRIAGE
LONGITUDINAL HOUSEHOLD
OTITIS-MEDIA
IMMUNOGENICITY
CHILDREN
DISEASE
SAFETY
IMMUNIZATION
PROTECTION

Access to Document

10.1016/j.vaccine.2009.10.151

Rodenburg2010Vaccine.pdfFinal publisher's version, 464 KB

Handle.net

Persistent link

Cite this

@article{7517ca61cac248779f062b995bff1e6d,

title = "Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses",

abstract = "In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (C) 2009 Elsevier Ltd. All rights reserved.",

keywords = "Pneumococcal conjugate vaccine, Immunogenicity, Reduced-dose schedules, STREPTOCOCCUS-PNEUMONIAE, NASOPHARYNGEAL CARRIAGE, LONGITUDINAL HOUSEHOLD, OTITIS-MEDIA, IMMUNOGENICITY, CHILDREN, DISEASE, SAFETY, IMMUNIZATION, PROTECTION",

author = "Rodenburg, {Gerwin D} and {van Gils}, {Elske J M} and Veenhoven, {Reinier H} and Nienke Jones and Irina Tcherniaeva and Eelko Hak and {van Alphen}, Loek and Berbers, {Guy A M} and Sanders, {Elisabeth A M}",

year = "2010",

month = feb,

day = "3",

doi = "10.1016/j.vaccine.2009.10.151",

language = "English",

volume = "28",

pages = "1391--1396",

journal = "Vaccine",

issn = "0264-410X",

publisher = "ELSEVIER SCI LTD",

number = "5",

}

TY - JOUR

T1 - Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses

AU - Rodenburg, Gerwin D

AU - van Gils, Elske J M

AU - Veenhoven, Reinier H

AU - Jones, Nienke

AU - Tcherniaeva, Irina

AU - Hak, Eelko

AU - van Alphen, Loek

AU - Berbers, Guy A M

AU - Sanders, Elisabeth A M

PY - 2010/2/3

Y1 - 2010/2/3

N2 - In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (C) 2009 Elsevier Ltd. All rights reserved.

AB - In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2,4 and 11 months and at 2, 3, 4 and 11 months of age,as measured by double adsorption ELISA. Pre- and post-booster levels following the 2 + 1 - and 3 + 1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>= 1.0 mu g/ml and >= 5.0 mu g/ml) and 19F (>= 5.0 mu g/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (C) 2009 Elsevier Ltd. All rights reserved.

KW - Pneumococcal conjugate vaccine

KW - Immunogenicity

KW - Reduced-dose schedules

KW - STREPTOCOCCUS-PNEUMONIAE

KW - NASOPHARYNGEAL CARRIAGE

KW - LONGITUDINAL HOUSEHOLD

KW - OTITIS-MEDIA

KW - IMMUNOGENICITY

KW - CHILDREN

KW - DISEASE

KW - SAFETY

KW - IMMUNIZATION

KW - PROTECTION

U2 - 10.1016/j.vaccine.2009.10.151

DO - 10.1016/j.vaccine.2009.10.151

M3 - Article

C2 - 19931382

VL - 28

SP - 1391

EP - 1396

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -